Did you mean aromatase inhibitor?
Displaying drugs 151 - 175 of 2437 in total
Midostaurin
Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors . It was...
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... Protein Kinase Inhibitors ... Tyrosine Kinase Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors …
Ivacaftor
Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012 , and by Health Canada in late 2012. Ivacaftor is administered...
Approved
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 CYP3A5 Inhibitors …
Orphenadrine
A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.
Approved
Matched Categories: … Enzyme Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2B6 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors …
Nitisinone
Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin.
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Hydroxyphenylpyruvate Dioxygenase Inhibitors ... 4-Hydroxyphenylpyruvate Dioxygenase, antagonists & inhibitors …
Teniposide
Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic...
Approved
Matched Categories: … Enzyme Inhibitors ... Topoisomerase Inhibitors ... Topoisomerase II Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors …
Leniolisib
Leniolisib is a potent and selective inhibitor of phosphoinositide 3-kinase δ (PI3Kδ). The FDA approved leniolisib on March 24, 2023, making it the first treatment for activated phosphoinositide 3-kinase delta syndrome (APDS). APDS is a primary immunodeficiency caused by mutations in genes encoding the PI3Kδ, thereby increasing the activity of...
Approved
Investigational
Matched Categories: … BCRP/ABCG2 Inhibitors ... OATP1B3 inhibitors ... OATP1B1/SLCO1B1 Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors …
Gemfibrozil
Gemfibrozil is a fibric acid agent, similar to clofibrate, used to treat Type IIb, IV, and V hyperlipidemias.[A185777,L8525] Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet, exercise, and other medications. Gemfibrozil was granted FDA approval on 21...
Approved
Matched Categories: … Enzyme Inhibitors ... UGT1A1 Inhibitors ... UGT1A3 Inhibitors ... OATP1B3 inhibitors ... OAT3/SLC22A8 Inhibitors …
Danazol
A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.
Approved
Matched Categories: … Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Thyroxine-binding globulin inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors (strong) …
Temsirolimus
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Approved
Matched Categories: … mTOR Inhibitors ... Enzyme Inhibitors ... P-glycoprotein inhibitors ... Protein Kinase Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors …
Tafenoquine
Tafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy group.[A35671, A35690] It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria. Tafenoquine was...
Approved
Investigational
Matched Categories: … MATE inhibitors ... OCT2 Inhibitors ... MATE 1 Inhibitors ... MATE 2 Inhibitors …
Fosnetupitant
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form...
Approved
Matched Categories: … Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors (moderate) …
Famotidine
Famotidine is a competitive histamine-2 (H2) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H2 receptor antagonists, famotidine displays high selectivity towards...
Approved
Matched Categories: … MATE inhibitors ... OCT2 Inhibitors ... MATE 1 Inhibitors ... OAT3/SLC22A8 Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors …
Artenimol
Artenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated Plasmodium falciparum infections [FDA Label]. It was first authorized for market by the European Medicines Agency in October 2011 in combination with DB13941 as the product Eurartesim. Artemisinin combination therapy is highly effective against malaria and...
Approved
Experimental
Investigational
Matched Categories: … Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors (weak) ... Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) …
Paritaprevir
Paritaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common...
Approved
Investigational
Matched Categories: … UGT1A1 Inhibitors ... BCRP/ABCG2 Inhibitors ... OATP1B3 inhibitors ... P-glycoprotein inhibitors ... NS3/4A Protease Inhibitors …
Amodiaquine
A 4-aminoquinoquinoline compound with anti-inflammatory properties.
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors (strength unknown) …
Erdafitinib
In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing...
Approved
Investigational
Matched Categories: … OCT2 Inhibitors ... P-glycoprotein inhibitors ... Protein Kinase Inhibitors ... Tyrosine Kinase Inhibitors ... Cytochrome P-450 CYP3A Inhibitors …
Fluticasone propionate
Fluticasone propionate is a synthetic glucocorticoid[F4355,F4358][FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358][FDA Label]. Fluticasone propionate was first approved in 1990 .
Approved
Matched Categories: … OATP1B1/SLCO1B1 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 CYP3A5 Inhibitors …
Clopidogrel
Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral...
Approved
Matched Categories: … OCT1 inhibitors ... OCT2 Inhibitors ... Cytochrome P-450 CYP2B6 Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors …
Desvenlafaxine
Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of venlafaxine. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of adults with major depressive disorder (MDD).[L6016,A261271]
MDD is a highly...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors ... Norepinephrine Uptake Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors …
Asunaprevir
Asunaprevir, also named BMS-650032, is a potent hepatitis C virus (HCV) NS3 protease inhibitor. It has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genotype 1b. It was developed by Bristol-Myers Squibb Canada and approved by Health Canada on...
Approved
Investigational
Withdrawn
Matched Categories: … Enzyme Inhibitors ... OATP1B3 inhibitors ... Protease Inhibitors ... HCV Protease Inhibitors ... HIV Protease Inhibitors …
Diethylstilbestrol
A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed)
The FDA withdrew its...
Approved
Investigational
Withdrawn
Matched Categories: … BCRP/ABCG2 Inhibitors ... OATP1B1/SLCO1B1 Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors …
Cariprazine
Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT1A receptors and as an antagonist at serotonin 5-HT2A receptors. Cariprazine has been investigated in a variety of psychiatric disorders,...
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors …
Lansoprazole
Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other pathologies...
Approved
Investigational
Matched Categories: … BCRP/ABCG2 Inhibitors ... Proton Pump Inhibitors ... Proton-pump Inhibitors ... OAT3/SLC22A8 Inhibitors ... P-glycoprotein inhibitors …
Glasdegib
Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionality. The great lipophilicity of this group of compounds...
Approved
Investigational
Matched Description: … In early research, benzimidazoles attracted large interest as they represented a class of inhibitors …
Matched Categories: … MATE inhibitors ... BCRP/ABCG2 Inhibitors ... MATE 1 Inhibitors ... MATE 2 Inhibitors ... P-glycoprotein inhibitors …
Matched Categories: … MATE inhibitors ... BCRP/ABCG2 Inhibitors ... MATE 1 Inhibitors ... MATE 2 Inhibitors ... P-glycoprotein inhibitors …
Atogepant
Atogepant is an oral antagonist of calcitonin gene-related peptide (CGRP) receptors indicated for the prevention of episodic migraine headaches. It was developed by AbbVie and received FDA approval under the brand name Qulipta in September 2021. While its approval was predated by two other members of the same drug family,...
Approved
Investigational
Matched Categories: … MATE inhibitors ... OCT1 inhibitors ... MATE 1 Inhibitors ... OATP1B3 inhibitors ... OATP1B1/SLCO1B1 Inhibitors …
Displaying drugs 151 - 175 of 2437 in total